Didier Mayeur

Didier Mayeur

Auto-generated profile, based on publicly available information

Didier Mayeur

Centre George François Leclerc -1, rue Professeur Marion-21079, Dijon, Cedex, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LGLoïck Galland
Loïck Galland
NRNicolas Roussot
Nicolas Roussot
IDIsabelle Desmoulins
Isabelle Desmoulins
DMDidier Mayeur
Didier Mayeur
CKCourèche Kaderbhai
Courèche Kaderbhai
SLSylvain Ladoire
Sylvain Ladoire
Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized treatment. Thanks to next-generation sequencing (NGS), progress in biomedical technologies, and the use of bioinformatics, it is now possible to identify specific molecular alterations in tumor cells—such as homologous recombination deficiencies (HRD)—enabling us to consider using DNA-damaging agents such as platinum salts or PARP inhibitors. Different approaches currently exist to analyze impairment of the homologous recombination pathway, e.g., the search for specific mutations in homologous recombination repair (HRR) genes, such as BRCA1/2; the use of genomic scars or mutational signatures; or the development of functional tests. Nevertheless, the role and value of these different tests in breast cancer treatment decisions remains to be clarified. In this review, we summarize current knowledge on the clinical utility of genomic tests, evaluating HRR deficiency for treatment decisions in early and metastatic breast cancer.

16 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LALe Marouille Alexandre
Le Marouille Alexandre
EPEmma Petit
Emma Petit
CKCourèche Kaderbhaï
Courèche Kaderbhaï
IDIsabelle Desmoulins
Isabelle Desmoulins
AHAudrey Hennequin
Audrey Hennequin
ASAntonin Schmitt
Antonin Schmitt
Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils from real-life palbociclib-treated patients. A population pharmacokinetic (popPK) model was first constructed to describe palbociclib pharmacokinetic (PK). Individual PK parameters obtained were then used in the pharmacokinetic/pharmacodynamic (PK/PD) model to depict the relation between palbociclib concentrations and absolute neutrophil counts (ANC). The models were built with a population of 143 patients. Palbociclib samples were routinely collected during therapeutic drug monitoring, whereas ANC were retrospectively retrieved from the patient files. The optimal popPK model was a mono-compartmental model with a first-order absorption constant of 0.187 h−1 and an apparent clearance Cl/F of 57.09 L (32.8% of inter individuality variability (IIV)). The apparent volume of distribution (1580 L) and the lag-time (Tlag: 0.658 h) were fixed to values from the literature. An increase in creatinine clearance and a decrease in alkaline phosphatase led to an increase in palbociclib Cl/F. To describe ANC kinetics during treatment, Friberg’s PK/PD model, with linear drug effect, was used. Parameters estimated were Base (2.92 G/L; 29.6% IIV), Slope (0.0011 L/µg; 28.8% IIV), Mean Transit Time (MTT; 5.29 days; 17.9% IIV) and γ (0.102). The only significant covariate was age on the initial ANC (Base), with lower ANC in younger patients. PK/PD model-based simulations show that the higher the estimated CressSS (trough concentration at steady state), the higher the risk of developing neutropenia. In order to present a risk lower than 20% to developing a grade 4 neutropenia, the patient should show an estimated CressSS lower than 100 µg/L.

24 February 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BRBernard Royer
Bernard Royer
CKCourèche Kaderbhaï
Courèche Kaderbhaï
JFJean-David Fumet
Jean-David Fumet
AHAudrey Hennequin
Audrey Hennequin
IDIsabelle Desmoulins
Isabelle Desmoulins
ASAntonin Schmitt
Antonin Schmitt
Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Its metabolism profile is associated with an important interpatient variability. We performed a population pharmacokinetics study of palbociclib in women routinely followed in a cancer center. One hundred and fifty-one samples were analyzed. The sampling times after administration ranged from 0.9 to 75 h and the samples were taken between 1 and 21 days after the beginning of the palbociclib cycle. Palbociclib was determined using a validated mass spectrometry method. The best model that described the concentrations was a one-compartment model with first-order absorption and an absorption lag time. Interindividual variability could only be estimated on the clearance and the first-order absorption. Creatinine clearance was found to be a significant covariate for the apparent clearance. No significant covariates could be observed with the first-order absorption. First-order absorption and absorption lag times were difficult to assess because of the constraints linked to the real-world setting due to the small number of samples used during the absorption process. However, palbociclib apparent clearance was satisfactorily estimated. Population pharmacokinetics (POP PK) with palbociclib could help to optimize dosing.

27 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Isabelle MahéIsabelle Mahé
Isabelle Mahé
CCCéline Chapelle
Céline Chapelle
LPLudovic Plaisance
Ludovic Plaisance
LBLaurent Bertoletti
Laurent Bertoletti
PMPatrick Mismetti
Patrick Mismetti
FCFrancis Couturaud
Francis Couturaud
Low molecular weight heparins (LMWHs) are recommended by international guidelines for at least 6 months in patients with cancer-associated thromboembolism (CAT). Direct oral anticoagulants (DOACs) have been proposed as an alternative to LMWH. In clinical practice, the specialists in charge of CAT have to decide which anticoagulant to prescribe. An electronic survey tool, including vignettes and questions, was sent to members of the French Society of Vascular Medicine, the French-speaking association for supportive care in oncology and the Investigation Network On Venous Thrombo-Embolism. Among the 376 respondents, LMWHs were reported as the first choice by most specialists. The prescription of DOACs within the first 3 weeks of CAT diagnosis was highly dependent on the cancer site: 5.9%, 18.6% and 24.5% in patients with locally advanced colorectal, lung and breast cancer, respectively. The determinants were mostly related to cancer (site and stage or evolution) and to anticancer treatments. For 61% of physicians, some anticancer treatments were contraindications to DOACs. However, almost 90% of physicians considered switching to DOAC after a median 3-month period of LMWHs. In daily practice, LMWHs and DOACs are now considered by specialists of CAT; the decision is mostly driven by the site of cancer. The role of anticancer treatments in the decision remains to be investigated.

9 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JBJeremy Baude
Jeremy Baude
JNJulie Niogret
Julie Niogret
PJPierre Jacob
Pierre Jacob
FBFlorian Bardet
Florian Bardet
IDIsabelle Desmoulins
Isabelle Desmoulins
SLSylvain Ladoire
Sylvain Ladoire
Background: Chemotherapy using carboplatin and etoposide (CE) is frequently pragmatically proposed to treat metastatic prostate cancer (mPC), both primary small-cell neuroendocrine (PSC-NE) carcinoma and adenocarcinoma with or without neuroendocrine (NE) marker elevation. However, the real benefit of CE is poorly reported in the recent therapeutic context. Methods: We retrospectively analyzed the efficacy and tolerance of CE chemotherapy in these three different groups of mPC patients. Efficacy endpoints included radiological response, progression-free survival (PFS), and overall survival (OS), as well as PSA response and PFS2/PFS1 ratio in patients with adenocarcinoma. Results: Sixty-nine patients were included in this single-center study (N = 18 with PSC-NE carcinoma and 51 with adenocarcinoma with (N = 18) or without (N = 33) NE marker elevation). Patients with adenocarcinoma were highly pretreated with next-generation hormonal agents (NHAs) and taxanes. In patients with adenocarcinoma, a PSA response ≥50% was observed in six patients (15.8%), four of whom had NE marker elevation. The radiological response was higher in PSC-NE and tended to be higher in adenocarcinoma when NE marker elevation was present. Comparing patients with adenocarcinoma with vs. without NE marker elevation, the median PFS was 3.7 and 2.1 months and the median OS was 7.7 and 4.7 months, respectively. Overall, 62.3% of patients experienced grade 3–4 adverse events (mainly hematological), and three treatment-related deaths were recorded. Conclusion: Reports of the clinical results of CE suggest that we should not mix PSC-NE and castration-resistant adenocarcinoma of the prostate. In patients with heavily pretreated adenocarcinoma, the benefit/risk ratio of CE chemotherapy seems unfavorable due to poor response and high toxicity.

15 January 2025 in Current Opinion in Oncology
Verified
Journal Article
Closed access
DMDidier Mayeur
Didier Mayeur
Purpose of review: New anticancer drugs often are associated with improved results, such as objective response and disease-free survival. But with these new drugs, patients, caregivers and medical oncologist have to face new toxicities, quite different from the side effects of conventional chemotherapy. The aim of this review is to share the actual knowledge about these new toxicities. Recent findings: We review here some of these new toxicities, as ocular, cardio, lung and mucocutaneous toxicities, as well as specific side effects of CAR-T cells. We also discuss a specific problem, which is financial toxicity. Summary: With this review, caregivers and medical oncologists will be aware of these new toxicities and able to develop their own network of specialized practitioners to provide the best possible supportive care.